Qiagen has announced the acquisition of Cellestis, a biotechnology firm based in Australia that is responsible for a number of innovative products.
The company has agreed to pay AU $341 million (219.42 million pounds) to take control of Cellestis, a transaction that will provide it with exclusive access to its QuantiFERON disease detection and monitoring technology.
This novel pre-molecular technology has already been successfully commercialised by Cellestis and will be migrated to Qiagen's QIAsymphony and QIAensemble platforms, providing new functionality that is not possible with other diagnostic methods.
Qiagen expects that this takeover will provide a fillip to its sales and earnings growth rates in 2012 via sales of QuantiFERON-based products.
Peer Schatz, chief executive officer of Qiagen, said: "We believe the addition of Cellestis will further strengthen our capabilities to offer innovative sample and assay technologies that are making improvements in life possible."
Last month, the company announced the proposal of healthcare veterans Dr Vera Kallmeyer and Elizabeth Tallett as members of its supervisory board.See all the latest jobs in Science